Avid Bioservices Inc (CDMO)

[sulaco]

SK: "Unique position for Bavi in I/O combination space"


If I've said it once, I've said it a thousand times:

It is precisely because Bavi is NOT a direct threat to future immune-oncology agents that its future success remains highly likely

THAT's why SK keeps saying we'll be right in the middle of the COMBINATION I/O space.

Combinations by definition involve partnerships. You get SOC out of these combinations, and we'll all be fine in my view.


Best,

Joe